2HQ Fundamental Analysis - TILRAY BRANDS INC

Fundamental Rating

Taking everything into account, 2HQ scores 2 out of 10 in our fundamental rating. 2HQ was compared to 55 industry peers in the Pharmaceuticals industry. The financial health of 2HQ is average, but there are quite some concerns on its profitability. 2HQ is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year 2HQ has reported negative net income.

2HQ had a negative operating cash flow in the past year.

In the past 5 years 2HQ always reported negative net income.

In the past 5 years 2HQ reported 4 times negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -103.13%, 2HQ is doing worse than 89.09% of the companies in the same industry.

The Return On Equity of 2HQ (-139.41%) is worse than 81.82% of its industry peers.

		Industry Rank	Sector Rank
ROA	-103.13%
ROE	-139.41%
ROIC	N/A

ROA(3y)-48.32%

ROA(5y)-36.47%

ROE(3y)-65.2%

ROE(5y)-55.79%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With a Gross Margin value of 28.69%, 2HQ is not doing good in the industry: 78.18% of the companies in the same industry are doing better.

2HQ's Gross Margin has improved in the last couple of years.

The Profit Margin and Operating Margin are not available for 2HQ so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	28.69%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y16.36%

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

2HQ does not have a ROIC to compare to the WACC, probably because it is not profitable.

2HQ has more shares outstanding than it did 1 year ago.

Compared to 5 years ago, 2HQ has more shares outstanding

Compared to 1 year ago, 2HQ has a worse debt to assets ratio.

2.2 Solvency

2HQ has an Altman-Z score of -1.75. This is a bad value and indicates that 2HQ is not financially healthy and even has some risk of bankruptcy.

2HQ has a Altman-Z score of -1.75. This is amonst the worse of the industry: 2HQ underperforms 80.00% of its industry peers.

2HQ has a Debt/Equity ratio of 0.18. This is a healthy value indicating a solid balance between debt and equity.

Looking at the Debt to Equity ratio, with a value of 0.18, 2HQ belongs to the top of the industry, outperforming 81.82% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0.18
Debt/FCF	N/A
Altman-Z	-1.75

ROIC/WACCN/A

WACC7.76%

2.3 Liquidity

A Current Ratio of 2.62 indicates that 2HQ has no problem at all paying its short term obligations.

2HQ has a better Current ratio (2.62) than 85.45% of its industry peers.

A Quick Ratio of 1.56 indicates that 2HQ should not have too much problems paying its short term obligations.

Looking at the Quick ratio, with a value of 1.56, 2HQ is in the better half of the industry, outperforming 80.00% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	2.62
Quick Ratio	1.56

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

2HQ shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -648.00%.

The Revenue has been growing slightly by 2.31% in the past year.

Measured over the past years, 2HQ shows a very strong growth in Revenue. The Revenue has been growing by 37.52% on average per year.

EPS 1Y (TTM)-648%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%100%

Revenue 1Y (TTM)2.31%

Revenue growth 3Y9.34%

Revenue growth 5Y37.52%

Sales Q2Q%4.73%

3.2 Future

Based on estimates for the next years, 2HQ will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.44% on average per year.

The Revenue is expected to grow by 4.31% on average over the next years.

EPS Next Y97.21%

EPS Next 2Y40.83%

EPS Next 3Y26.48%

EPS Next 5Y15.44%

Revenue Next Year3.68%

Revenue Next 2Y4.08%

Revenue Next 3Y4.04%

Revenue Next 5Y4.31%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

2HQ reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for 2HQ. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, 2HQ is valued a bit more expensive than 67.27% of the companies in the same industry.

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	21.11

4.3 Compensation for Growth

2HQ's earnings are expected to grow with 26.48% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y40.83%

EPS Next 3Y26.48%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for 2HQ!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

TILRAY BRANDS INC

FRA:2HQ (12/1/2025, 7:00:00 PM)

0.679

-0.04 (-5.19%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)10-09 2025-10-09/bmo

Earnings (Next)01-08 2026-01-08/bmo

Inst Owners9.86%

Inst Owner ChangeN/A

Ins Owners0.36%

Ins Owner ChangeN/A

Market Cap762.42M

Revenue(TTM)830.77M

Net Income(TTM)-2.15B

Analysts71.25

Price Target1.67 (145.95%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)-2631.48%

Min EPS beat(2)-5362.97%

Max EPS beat(2)100%

EPS beat(4)1

Avg EPS beat(4)-1385.84%

Min EPS beat(4)-5362.97%

Max EPS beat(4)100%

EPS beat(8)2

Avg EPS beat(8)-708.23%

EPS beat(12)2

Avg EPS beat(12)-746.7%

EPS beat(16)4

Avg EPS beat(16)-606.4%

Revenue beat(2)1

Avg Revenue beat(2)-3.41%

Min Revenue beat(2)-7.23%

Max Revenue beat(2)0.41%

Revenue beat(4)1

Avg Revenue beat(4)-6.19%

Min Revenue beat(4)-13.28%

Max Revenue beat(4)0.41%

Revenue beat(8)1

Avg Revenue beat(8)-5.71%

Revenue beat(12)2

Avg Revenue beat(12)-3.59%

Revenue beat(16)2

Avg Revenue beat(16)-3.93%

PT rev (1m)86%

PT rev (3m)102.16%

EPS NQ rev (1m)0%

EPS NQ rev (3m)11.11%

EPS NY rev (1m)1.18%

EPS NY rev (3m)61.82%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)-1.44%

Revenue NY rev (1m)0.04%

Revenue NY rev (3m)-0.11%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	1.07
P/FCF	N/A
P/OCF	N/A
P/B	0.57
P/tB	1.16
EV/EBITDA	21.11

EPS(TTM)-1.29

EYN/A

EPS(NY)-0.02

Fwd EYN/A

FCF(TTM)-0.07

FCFYN/A

OCF(TTM)-0.05

OCFYN/A

SpS0.64

BVpS1.18

TBVpS0.58

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-103.13%
ROE	-139.41%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	28.69%
FCFM	N/A

ROA(3y)-48.32%

ROA(5y)-36.47%

ROE(3y)-65.2%

ROE(5y)-55.79%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y16.36%

GM growth 5YN/A

F-Score3

Asset Turnover0.4

Health

		Industry Rank	Sector Rank
Debt/Equity	0.18
Debt/FCF	N/A
Debt/EBITDA	6.5
Cap/Depr	30.45%
Cap/Sales	4.3%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.62
Quick Ratio	1.56
Altman-Z	-1.75

F-Score3

WACC7.76%

ROIC/WACCN/A

Cap/Depr(3y)21.23%

Cap/Depr(5y)65.01%

Cap/Sales(3y)3.68%

Cap/Sales(5y)7.53%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-648%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%100%

EPS Next Y97.21%

EPS Next 2Y40.83%

EPS Next 3Y26.48%

EPS Next 5Y15.44%

Revenue 1Y (TTM)2.31%

Revenue growth 3Y9.34%

Revenue growth 5Y37.52%

Sales Q2Q%4.73%

Revenue Next Year3.68%

Revenue Next 2Y4.08%

Revenue Next 3Y4.04%

Revenue Next 5Y4.31%

EBIT growth 1Y28.53%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year109.7%

EBIT Next 3Y29.12%

EBIT Next 5Y17.36%

FCF growth 1Y-688.1%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-258.17%

OCF growth 3YN/A

OCF growth 5YN/A

TILRAY BRANDS INC / 2HQ.DE FAQ

What is the fundamental rating for 2HQ stock?

ChartMill assigns a fundamental rating of 2 / 10 to 2HQ.DE.

Can you provide the valuation status for TILRAY BRANDS INC?

ChartMill assigns a valuation rating of 1 / 10 to TILRAY BRANDS INC (2HQ.DE). This can be considered as Overvalued.

Can you provide the profitability details for TILRAY BRANDS INC?

TILRAY BRANDS INC (2HQ.DE) has a profitability rating of 1 / 10.

Can you provide the financial health for 2HQ stock?

The financial health rating of TILRAY BRANDS INC (2HQ.DE) is 4 / 10.

TILRAY BRANDS INC (2HQ.DE) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

TILRAY BRANDS INC / 2HQ.DE FAQ

What is the fundamental rating for 2HQ stock?

Can you provide the valuation status for TILRAY BRANDS INC?

Can you provide the profitability details for TILRAY BRANDS INC?

Can you provide the financial health for 2HQ stock?